Commercial analytics and forecasting underpin strategic decision-making and business planning across the pharmaceutical and life science sectors. Inaccurate risk assessments and poor strategic decision making cost the industry billions of dollars in wasted R&D spend every year and result in a gap in pharmaceutical intelligence to inform decision making in the clinical development space.
But what’s the alternative? How can you forecast the commercial potential of early-stage assets more effectively?
The short answer is intelligent forecasting. Essentially, a blend of machine learning and human ingenuity that considers the past, present and future drivers of commercial and clinical success in real time.
In this white paper we shed light on the “black box” that is machine learning, bust some myths about what it is (and what it isn’t) and show how it can add huge value across the pharmaceutical value chain.
Download Now
Share
Related Blogs
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...
Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our ...
